Related Experiment Video
Updated: May 19, 2026

Assessing Stem Cell DNA Integrity for Cardiac Cell Therapy
Published on: January 25, 2019
Removing the cells from adult bone marrow derived stem cell therapy does not eliminate cardioprotection
1Department of Cardiothoracic Surgery, London Chest Hospital, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK. 92myasin@gmail.com
Insights
Adult bone marrow stem cells and their supernatant offer cardioprotection against heart injury. This suggests non-regenerative benefits of stem cell therapy in treating myocardial ischemia-reperfusion injury.
Area of Science:
- Cardiovascular Research
- Regenerative Medicine
- Stem Cell Biology
Background:
- The regenerative potential of adult stem cell therapy remains debated.
- Adult bone marrow-derived stem cells are being investigated for therapeutic benefits.
- Myocardial ischemia-reperfusion injury is a significant clinical challenge.
Purpose of the Study:
- To investigate the non-regenerative benefits of adult bone marrow-derived stem cell therapy.
- To determine if the supernatant from bone marrow mononuclear cells (BMMNC) is cardioprotective.
- To evaluate the effects in an animal model of myocardial ischemia-reperfusion injury.
Main Methods:
- Wistar rats underwent LAD occlusion and reperfusion to model myocardial injury.
- Bone marrow mononuclear cells (BMMNC) and their supernatant (BMS) were administered intravenously.
- Infarct size was measured, and proteomic analysis identified protein expression changes.
Main Results:
- BMMNC supernatant (BMS) significantly reduced infarct size (34% vs. 57% in controls).
- BMMNC administration also reduced infarct size (33% vs. 57% in controls).
- Proteomic analysis revealed increased expression of anti-apoptotic, antioxidant, heat shock, glycolytic, and mitochondrial proteins.
Conclusions:
- Intravenous administration of BMMNC or BMS attenuates myocardial reperfusion injury.
- Adult stem cells appear to mediate non-regenerative cardioprotection.
- These findings contribute to understanding stem cell therapy mechanisms beyond regeneration.
Objectives:
The debate as to whether adult stem cell therapy is regenerative or not continues. The non-regenerative benefits of adult bone marrow-derived stem cell therapy were investigated by testing whether the supernatant derived from unfractionated bone marrow mononuclear cells might be cardioprotective in an animal model of myocardial ischaemia-reperfusion injury.
Methods:
Regional myocardial reperfusion injury was acquired by 25 min reversible left anterior descending coronary artery (LAD) occlusion followed by 2 h reperfusion, in anaesthetized Wistar male rats. Unfractionated bone marrow mononuclear cells (BMMNC) isolated from sibling Wistar male rat whole bone marrow were phenotyped by fluorescence activated cell sorting flowcytometry for the haematopoietic stem cell surface markers c-kit, CD34, CD45 and CD133. Animals subjected to regional myocardial reperfusion injury received either 10 million BMMNC or BMMNC supernatant (BMS); both were collected in 0.5 ml phosphate-buffered saline and delivered by intravenous bolus at the onset of reperfusion. The left ventricular region distal to the LAD occlusion point was excised for measurement of myocardial infarct size and proteomic analysis, which was used to identify whether there were any differences in myocardial proteins associated with intravenous injection of either BMMNC or BMS.
Results:
BMMNC were phenotyped to be c-kit(+) (7 ± 1%), CD34(+) (7 ± 1%), CD45(+) (54 ± 6%), CD133(+) (15 ± 1%). The supernatant reduced myocardial infarct size (BMS 34 ± 2%, n = 15 vs control 57 ± 2%, n = 7, P < 0.0001), which was comparable to the reduction in infarct size afforded by the injection of cells (BMMNC 33 ± 3% vs control 57 ± 2%, n = 10, P < 0.0001). Proteomics of hearts treated with either BMS or BMMNC demonstrated higher expression of (i) anti-apoptotic signal transduction protein: 14-3-3-epsilon (1.5-fold); (ii) anti-oxidants: peroxiredoxin-6 (2.1-fold); (iii) heat shock proteins: alpha B-crystallin (1.7-fold), heat shock protein 72 (2.8-fold), tumour necrosis factor receptor-1 associated protein (2.3-fold), ischaemia responsive protein-94 (1.6-fold); (iv) glycolytic protein: glyceraldehyde-3-phosphate dehydrogenase (2.3-fold); (v) mitochondrial respiratory proteins: mitochondrial aconitase (4.7-fold), voltage-dependent anion-selective channel protein-1 (VDAC-1) (2.7-fold).
Conclusions:
Regional myocardial reperfusion injury can be attenuated by intravenous administration of either BMMNC or BMS at the onset of reperfusion, which suggests adult stem cells mediate non-regenerative cardioprotection.
Related Concept Videos
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Stem Cell Culture
Regulation of Hematopoietic Stem Cells
Multipotency of Hematopoietic Stem Cells
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Mesenchymal Stem Cells

